Deutsche Bank downgraded shares of Teladoc (NYSE:TDOC) from a buy rating to a hold rating in a report issued on Thursday morning. Deutsche Bank currently has $45.00 target price on the health services provider’s stock.
TDOC has been the topic of a number of other research reports. Oppenheimer raised their price target on Teladoc from $40.00 to $45.00 and gave the stock an outperform rating in a report on Tuesday, November 21st. KeyCorp reaffirmed a buy rating and issued a $41.00 price objective on shares of Teladoc in a report on Wednesday, January 10th. Citigroup initiated coverage on Teladoc in a report on Thursday, January 4th. They issued a buy rating on the stock. BidaskClub lowered Teladoc from a hold rating to a sell rating in a report on Wednesday, November 15th. Finally, Cantor Fitzgerald reaffirmed a hold rating and issued a $35.00 price objective (up previously from $31.00) on shares of Teladoc in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $41.36.
Teladoc (NYSE TDOC) traded down $0.40 during midday trading on Thursday, hitting $42.10. The company had a trading volume of 410,199 shares, compared to its average volume of 1,158,401. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.87 and a current ratio of 3.87. Teladoc has a 52-week low of $22.50 and a 52-week high of $44.65. The stock has a market capitalization of $2,651.15, a price-to-earnings ratio of -22.49 and a beta of 0.36.
In other news, President Peter A. Mcclennen sold 27,533 shares of Teladoc stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $43.01, for a total transaction of $1,184,194.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Goldstein sold 66,574 shares of Teladoc stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $39.72, for a total transaction of $2,644,319.28. Following the sale, the director now owns 54,325 shares of the company’s stock, valued at $2,157,789. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 364,494 shares of company stock valued at $14,665,947. Insiders own 4.47% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Xact Kapitalforvaltning AB acquired a new stake in shares of Teladoc during the 4th quarter valued at approximately $203,000. Envestnet Asset Management Inc. lifted its position in shares of Teladoc by 41.8% during the 4th quarter. Envestnet Asset Management Inc. now owns 13,402 shares of the health services provider’s stock valued at $467,000 after acquiring an additional 3,949 shares during the period. MetLife Investment Advisors LLC acquired a new stake in shares of Teladoc during the 4th quarter valued at approximately $883,000. Gotham Asset Management LLC acquired a new stake in shares of Teladoc during the 4th quarter valued at approximately $277,000. Finally, Redmile Group LLC acquired a new stake in shares of Teladoc during the 4th quarter valued at approximately $5,228,000.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.